References

References

1. World Health Organization. The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. In History of International Public Health No. 4. Geneva, World Health Organization, 1980. (pdf)

2. W.E. de Korte. Amaas or kaffir milk-pox. Lancet 1904. 1: 1273-1276.

3. C.V. Chapin. Variation in type of infectious disease as shown by the history of smallpox in the United States 1895

1912. Infect Dis 1913. 13: 171-196.

4. Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication. Geneva, World Health Organization, 1988. (Book)

5. McNeill WH. Plagues and People. Garden City, NY, Anchor Press/Doubleday, 1976.

6. Ruffer MA. Pathological note on the royal mummies of the Cairo Museum. In Moodie RL (ed). Studies in the Paleopathology of Egypt. Chicago, University of Chicago Press, 1921, pp 175-176.

7. Hopkins DR. Princes and Peasants. Smallpox in History. Chicago, University of Chicago Press, 1983.

8. Rhazes (Al-Razi, Abu Bakr Muhammad ibn Zakariya). De Variohs et Morbillis Commentarius. Londini, G Bowyer, 1766. English translation: Med Class 4:22

84, 1939.

9. Dixon CW. Smallpox. London, Churchill, 1962. (pdf)

10. Moore J. The History of the Smallpox. London, Longman, Hurst, Rees, Orme & Brown, 1815.

11. Creighton C. History of Epidemics in Britain. Cambridge, Cambridge University Press, 1894. Reprinted London, Cass, 1965.

12. Macgowan DJ. Report on the health of Wenchow for the half-year ended 31 March 1884. China, Imperial Maritime Customs Medical Reports 27:9

18, 1884.

13. Needham J. China and the origins of immunology. Centre of Asian Studies Occasional Papers and Monographs No. 41, University of Hong Kong, 1980.

14. G. Miller. Putting Lady Mary in her place: A discussion of historical causation Bull Hist Med 1981. 55: 2-16. (PubMed)

15. Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England. Particularly Gloucestershire and Known by the Name of the Cow Pox. London, 1798. Reprinted in Camac CNB (ed). Classics of Medicine and Surgery. New York, Dover, 1959.

16. Pasteur L. Vaccination in relation to chicken-cholera and splenic fever. Transactions of the International Medical Congress; Seventh Session; London; August 29, 1881, 1:85

90. Reproduced in Vallery-Radot P (ed). Oeuvres de Pasteur. Vol. 6. Paris, Masson, 1933, pp 370

378.

17. LeFanu W. A Bio-Bibliography of Edward Jenner 1749

1823. London, Harvey & Blythe, 1951.

18. del Castillo FF. Los Viajes de Don Francisco Xavier de Balmis. Mexico, Galas de Mexico, 1960.

19. J.Z. Bowers. The odyssey of smallpox vaccination Bull Hist Med 1981. 55: 17-33. (PubMed)

20. J.C. Nott. Smallpox epidemic in Mobile during the winter of 1865

6 Nashville J Med Surg 1867. 2: 372-380.

21. Creighton C. The Natural History of Cow-Pox and Vaccinal Syphilis. London, Cassell, 1887.

22. D. Baxby. The origins of vaccinia virus J Infect Dis 1977. 136: 453-455. (PubMed)

23. The History of Inoculation and Vaccination. London, Burroughs Wellcome Company, 1913.

24. Edwardes EJ. A Concise History of Small-Pox and Vaccination in Europe. London, Lewis, 1902.

25. Galbiati G. Memoria Sulla Inoculazione Vaccina coll'Umore Ricavato Immediatement dalla Vacca Precedentemente Inoculata. Napoli, 1810.

26. Congrès Medical de Lyon. Compterendu des travaux et des discussions. Gazette Med Lyon 19:449

47 1, 1864.

27. J.A. Dudgeon. Development of smallpox vaccine in England in the eighteenth and nineteenth centuries BMJ 1963. 1: 1367-1372. (PubMed)

28. L. Otten. Trockenlymphe Z_Hyg Infektioskrankh 1927. 107: 677-696.

29. R. Fasquelle and A. Fasquelle. A propos de l'histoire de la lutte contre la variole dans lees pays d'Afrique francophone Bull Soc Pathol Exot Filiales 1971. 64: 734-756. (PubMed)

30. L.H. Collier. The development of a stable smallpox vaccine J Hyg (Lond) 1955. 53: 76-101. (PubMed)

31. Pan American Sanitary Organization. Final Reports of the First Second and Third Meetings of the Directing Council. Publication No. 247. Washington, DC, Pan American Sanitary Organization, 1950.

32. World Health Organization. Eradication of Smallpox. Official Records of the World Health Organization No. 87. Geneva, World Health Organization, 1958, pp 263

264, 508

512.

33. World Health Organization. Smallpox Eradication. Official Records of the World Health Organization No. 95. Geneva, World Health Organization, 1959, pp 572

588.

34. World Health Organization. Official Records of the World Health Organization No. 152. Geneva, World Health Organization, 1966, p 291.

35. World Health Organization. Handbook for Smallpox Eradication in Endemic Areas. Geneva, World Health Organization, 1967.

36. D.A. Henderson. The eradication of smallpox Sci Am 1976. 235: 25-33. (PubMed)

37. D.A. Henderson. A discussion on technologies for rural health. Smallpox eradication Proc R Soc Lond B Biol Sci 1977. 199: 83-97. (PubMed)

38. Henderson DA The Deliberate Extinction of a Species. Philadelphia, American Philosophical Society, 1982.

39. A. Deria, Z. Jezek, and K. Markvart, et al. The world's last endemic case of smallpox: Surveillance and containment measures Bull World Health Organ 1980. 58: 279-283. (PubMed)

40. Shooter RA. Report of the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence. London, Her Majesty's Stationery Office, 1980. (pdf)

41. Basu RN, Jezek Z, Ward NA. The eradication of smallpox from India. In History of International Public Health No. 2. New Delhi, World Health Organization, South-East Asia Regional Office, 1979.

42. Brilliant LB. The Management of Smallpox Eradication in India. A Case Study and Analysis. Ann Arbor, University of Michigan Press, 1985.

43. Joarder AK, Tarantola D, Tulloch J. The Eradication of Smallpox from Bangladesh. World Health Organization Regional Publications South-East Asia Series No. 8. New Delhi, World Health Organization South-East Asia Regional Office, 1980.

44. Tekeste Y, Hailu A, do Amaral C, et al. Smallpox Eradication in Ethiopia. Brazzaville, World Health Organization, 1984.

45. Jezek Z, AlAghbari M, Hatfield R, et al. Smallpox Eradication in Somalia. Alexandria, World Health Organization Eastern Mediterranean Regional Office and Ministry of Health, Somali Democratic Republic, 1981.

46. Nakano JH. Human poxvirus diseases. In Lennette EH (ed). Laboratory Diagnosis of Viral Infections. New York, Marcel Dekker, 1985, pp 401

423.

47. N. Hahon. Cytopathogenicity and propagation of variola virus in tissue culture J Immunol 1958. 81: 426-32. (PubMed)

48. J.B. Pirsch, L.A. Mika, and E.H. Purlson. Growth characteristics of variola virus in tissue culture J Infect Dis 1963. 113: 170-178. (PubMed)

49. World Health Organization. Guide to the Laboratory Diagnosis of Smallpox for Smallpox Eradication Programmes. Geneva, World Health Organization, 1969.

50. A.W. Downie, L. St Vincent, A.R. Rao, and C.H. Kempe. Antibody response following smallpox vaccination and revaccination J Hyg (Lond) 1969. 67: 603-606. (PubMed)

51. A.W. Downie, L. St Vincent, and L. Goldstein et al. Antibody response in nonhaemorrhagic smallpox patients J Hyg (Lond) 1969. 67: 609-618. (PubMed)

52. K. McCarthy, A.W. Downie, and W.H. Bradley. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination J Hyg (Lond) 1958. 56: 466-478. (PubMed)

53. A.W. Downie, K. McCarthy, and A. Macdonald et al. Virus and virus antigen in the blood of smallpox patients. Their significances in early diagnosis and prognosis Lancet 1978. 2: 164-166. (PubMed)

54. E. White. Chickenpox in Kerala Indian J Public Health 1978. 22: 141-151. (PubMed)

55. Z. Jezek, R.N. Basu, and Z.S. Arya. Problem of persistence of facial pock marks among smallpox patients Indian J Public Health 1978. 22: 95-101. (PubMed)

56. Z. Jezek and W. Hardjotanojo. Residual skin changes in patients who have recovered from variola minor Bull World Health Organ 1980. 58: 139-140. (PubMed)

57. A.C. Mitra, J.K. Sarkar, and M.K. Mukheriee. Virus content of smallpox scabs Bull World Health Organ 1974. 51: 106-107. (PubMed)

58. W. Anders and J. Posch. Die Pockenausbrucke 1961/62 in Nordrhein-Westfalen Bundesgesundheitbl 1962. 17: 265-269.

59. P.F. Wehrle, J. Posch, K.H. Richter, and D.A. Henderson. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe Bull World Health Organ 1970. 43: 669-679. (PubMed)

60. F. Huq. Effect of temperature and relative humidity on variola virus in crusts Bull World Health Organ 1976. 54: 710-712. (PubMed)

61. G.J. Harper. Airborne micro-organisms: Survival tests with four viruses J Hyg (Lond) 1961. 59: 479-486. (PubMed)

62. L. Rogers. Smallpox and vaccination in British India during the last seventy years Proc R Soc Lond 1944. 38: 135-139.

63. Hope R.E. Simpson. Infectiousness of communicable diseases in the household (measles, chickenpox and mumps) Lancet 1952. 2: 549-554. (PubMed)

64. Carvalho E.S. de Filho, L. Morris, and Lavigne A. de Lemos et al. Smallpox eradication in Brazil, 1967

69 Bull World Health Organ 1970. 43: 797-808. (PubMed)

65. G.G. Heiner, N. Fatima, and R.W. Daniel et al. A study of inapparent infection in smallpox Am J Epidemiol 1971. 94: 252-268. (PubMed)

66. R.H. Henderson and M. Yekpe. Smallpox transmission in southern Dahomey. A study of a village outbreak Am J Epidemiol 1969. 90: 423-428. (PubMed)

67. D.B. Thomas, W.M. McCormack, and I. Arita et al. Endemic smallpox in rural East Pakistan. I. Methodology, clinical and epidemiologic characteristics of cases, and intervillage transmission Am J Epidemiol 1971. 93: 361-372. (PubMed)

68. D.B. Thomas, I. Arita, and W.M. McCormack et al. Endemic smallpox in rural East Pakistan. II. Intravillage transmission and infectiousness Am J Epidemiol 1971. 93: 373-383. (PubMed)

69. D.B. Thomas, T.M. Mack, A. Ali, and M.M. Khan. Epidemiology of smallpox in West Pakistan. III. Outbreak detection and interlocality transmission Am J Epidemiol 1972. 95: 178-189. (PubMed)

70. W.H. Foege, J.D. Millar, and D.A. Henderson. Smallpox eradication in west and central Africa Bull World Health Organ 1975. 52: 209-222. (PubMed)

71. Sencer DJ, Axnick NW. Cost-benefit analysis. In International Symposium on Vaccination Against Communicable Symposia Series in Immunobiological Standardization 22:37

46, 1973.

72. Stojkovic L, Birtasevic B, Borjanovic S, et al (eds). Variola u Jugosiaviji 1972 Godine. Ljubljana, CCP Delo, 1974.

73. T.M. Mack. Smallpox in Europe, 1950

1971 J Infect Dis 1972. 125: 161-169. (PubMed)

74. United Kingdom, Ministry of Health. Report of the Committee on Vaccination. London, His Majesty's Stationery Office, 1928.

75. A. Herrlich, A. Mayr, H. Mahnel, and E. Munz. Experimental studies on transformation of the variola virus into the vaccinia virus Arch Gesamte Virusforsch 1963. 12: 579-599. (PubMed)

76. Baxhy D. Jenner's Smallpox Vaccine. The Riddle of the Origin of Vaccinia Virus. London, Heinemann, 1981.

77. T.M. Rivers. Cultivation of vaccine virus for Jennerian prophylaxis in man J Exp Med 1931. 54: 453-461.

78. Barker LF. Further attenuated vaccinia virus: A possible alternative for primary immunization. In Sixth Annual Immunization Conference; Atlanta, GA; March 11

13, 1969, p 55.

79. T.M. Rivers and S.M. Ward. Jennerian prophylaxis by means of intradermal injections of cultured vaccine virus J Exp Med 1935. 62: 549-560.

80. T.M. Rivers, S.M. Ward, and R.D. Baird. Amount and duration of immunity induced by intradermal inoculation of cultured vaccine virus J Exp Med 1939. 69: 857-866.

81. J. van der Noordaa, F. Dekking, J. Posthuma, and B.J.W. Beunders. Primary vaccination with an attenuated strain of vaccinia virus Arch Gesamte Virusforsch 1967. 22: 210-214. (PubMed)

82. C.H. Kempe, V. Fulginiti, M. Minamitani, and H. Shinefeld. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CV-178) Pediatrics 1968. 42: 980-989. (PubMed)

83. H. Tint. The rationale for elective prevaccinadon with attenuated vaccine (CV-178) in preventing some vaccination complications. In International Symposium on Smallpox Vaccine Symposia Series in Immunobiological Standardization 1973. 19: 281-292.

84. G.J. Galasso, D.T. Karzon, and S.L. Katz et al. (eds). Clinical and serological study of four smallpox vaccines comparing variations of dose and route of administration J Infect Dis 1977. 135: 183-186. (PubMed)

85. McIntosh K. A comparative study of four smallpox vaccines in children. In Quinnan GV Jr (ed). Vaccinia Viruses as Vectors for Vaccine Antigens. New York, Elsevier, 1985, pp 77

84.

86. V. Hochstein-Mintzel, T. Hanichen, and H.C. Huber et al. Vaccinia-und variolaprotektive Wirkung des modifizierten Vaccinia-Stam-mes MVA bei intramuskularer Immunisierung Zentralbl Bakteriol Orig A 1975. 230: 283-297. (PubMed)

87. A. Mayr, H. Stickl, and H.K. Muller et al. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism Zentralbl Bakteriol [B] 1978. 167: 375-390. (PubMed)

88. S. Hashizume. A new attenuated strain of vaccinia virus, LC 16m8: Basic information [in Japanese] J Clin Virol 1975. 3: 229-235.

89. S. Hashizume, H. Yoshizawa, M. Morita, and K. Suzuki. Properties of attenuated mutant of vaccinia virus, LC 16m8, derived from Lister strain. In Quinnan GV Jr (ed). Vaccinia Viruses as Vectors for Vaccine Antigens New York, Elsevier 1985. 87-99.

90. Kato S. Low neurovirulent variant of Lister strain of vaccinia virus. In Quinnan GV Jr (ed). Vaccinia Viruses as Vectors for Vaccine Antigens. New York, Elsevier, 1985, pp 85

86.

91. Japan, Ministry of Health . Report of Committee on Smallpox Vaccination. Investigation of treatment of complications caused by smallpox vaccination [in Japanese] Clin Virol 1975. 3: 269-278.

92. A.C. Hekker, J.M. Bos, and L. Smith. A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells J Biol Stand 1973. 1: 21-32.

93. Hekker AC, Huisman J, Polak MF, et al. Field work with a stable freeze-dried vaccine prepared in monolayers of rabbit kidney cells. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological standardisation 19:187

195, 1973.

94. A.C. Hekker, J.M. Bos, and N. Rai Kumara, et al. Large-scale use of freeze-dried smallpox vaccine prepared in primary cultures of rabbit kidney cells Bull World Health Organ 1976. 54: 279-284. (PubMed)

95. R.M. Cross, C. Kaplan, and D. McClean. The heat resistance of dried smallpox vaccine Lancet 1957. 1: 446-448. (PubMed)

96. A.W. Downie and K. McCarthy. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox J Hyg (Lond) 1958. 56: 479-487. (PubMed)

97. W.B. Pincus and J.A. Flick. The role of hypersensitivity in the pathogenesis of vaccinia virus in humans J Pediatr 1963. 62: 57-62. (PubMed)

98. R.J. Blattner, J.O. Norman, F.M. Heys, and I. Aksu. Antibody response to cutaneous inoculation with vaccinia virus: Viremia and viruria in vaccinated children J Pediatr 1964. 64: 839-852. (PubMed)

99. H.A. Gins, H. Hackenthal, and N. Kamentzewa. Experimentelle Untersuchungen fiber die Generalisierung des Vaccine-Virus beim Menschen und Versuchstier Z Hyg Infectionskrankh 1929. 110: 429-441.

100. A.S. Benenson. Immediate (so-called "immune") reaction to smallpox vaccination J Am Med Assoc 1950. 143: 1238-1249. (PubMed)

101. WHO Expert Committee on Smallpox. First report. WHO Technical Report Series No. 283. Geneva, World Health Organization, 1964.

102. Hanna W. Studies in Smallpox and Vaccination. Bristol, Wright, 1913.

103. Rao A.R. Smallpox. Bombay, The Kothari Book Depot, 1972. (pdf)

104. V. Zikmund, N. Das, R. Krishnayengar, and B. Rao Kameswara. Contribution to the problem of challenge vaccination. Observations on vaccination of cured smallpox cases in India in 1971, 1972 and 1973 Indian J Public Health 1978. 22: 102-106. (PubMed)

105. P.A. Winter, J.H. Mason, and E. Kuhr, et al. Combined immunization against poliomyelitis, diphtheria, whooping cough, tetanus and smallpox S Afr Med J 1963. 37: 513-515. (PubMed)

106. A.W. Karchmer, J.P. Friedman, and H.L. Casey, et al. Simultaneous administration of live virus vaccines. Measles, mumps, poliomyelitis and smallpox Am J Dis Child 1971. 121: 382-388. (PubMed)

107. H.T. Lin. A study of the effect of simultaneous vaccination with BCG and smallpox vaccine in newborn infants Bull World Health Organ 1965. 33: 321-336. (PubMed)

108. P.D. Meers. Further observations on 17D-yellow fever vaccination by scarification, with and without simultaneous smallpox vaccination Transfusion (Paris) 1960. 54: 493-501. (PubMed)

109. J.G. Breman, E. Coffi, and K.R. Bomba-Ires, et al. Evaluation of a measles-smallpox vaccination campaign by a seroepidemiologic method Am J Epidemiol 1975. 102: 564-571. (PubMed)

110. H.M. Meyer Jr, D.D. Hostetler Jr, and B.C. Bernheim, et al. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines Bull World Health Organ 1964. 30: 783-794. (PubMed)

111. F.L. Ruben, E.A. Smith, and S.O. Foster, et al. Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children Bull World Health Organ 1973. 48: 175-181. (PubMed)

112. W.H. Foege and S.O. Foster. Multiple antigen vaccine strategies in developing countries Am J Trop Med Hyg 1974. 23: 685-689. (PubMed)

113. J.M. Lane, F.L. Ruben, J.M. Neff, and J.D. Millar. Complications of smallpox vaccination, 1968. National surveillance in the United States N Engl J Med 1969. 281: 1201-1208. (PubMed)

114. J.M. Lane, F.L. Ruben, J.M. Neff, and J.D. Millar. Complications of smallpox vaccination, 1968: Results of ten statewide surveys J Infect Dis 1970. 122: 303-309. (PubMed)

115. C.H. Kempe. Studies on smallpox and complications of smallpox vaccination Pediatrics 1960. 26: 176-189. (PubMed)

116. H.D. Brainerd, L. Hanna, and E. Jawetz. Methisazone in progressive vaccinia N Engl J Med 1967. 276: 620-622. (PubMed)

117. Wilson G.S. The Hazards of Immunization. London, Athlone, 1967.

118. de Vries E. Post-vaccinal Perivenous Encephalitis. Amsterdam, Elsevier, 1960.

119. G. Weber and J. Lange. Zur Variationsbreite der "Inkubationszeiten" postvakzinaler zerebraler Erkrankungen Dtsch Med Wochenschr 1961. 86: 1461-1468. (PubMed)

120. Polak MF. Complications of smallpox vaccination in the Netherlands, 1959

1970. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization 19:235

242, 1973. (pdf)

121. K. Berger and F. Puntigam. Uber die Erkrankungshaufigkeit verschiedener Altersklassen von Erstimpflingen an postvakzinaler Enzephalitis nachsubcutaner Pockenschutzimpfung Wien Med 1954. 104: 487-492.

122. E.T. Conybeare. Illnesses attributed to smallpox vaccination, 1951

1960. Part II. Illnesses reported as affecting the central nervous system Monthly Bulletin of the Ministry of Health and the Public Health Laboratory Service 1964. 23: 150-159. (PubMed)

123. A. Herrlich. Probleme der Pocken and Pockenschutzimpfung Munch Med Wochenschr 1954. 96: 529-533. (PubMed)

124. G. Stuart. Memorandum on postvaccinal encephalitis Bull World Health Organ 1947

1948. 1: 36-53.

125. Femmer J. Cited by Wilson G.S. Hazards of Immunization. London, Athlone, 1967.

126. K. Seeleman. Zerebrale Komplikationen nach Pock-enschutzimpfungen mit besonderer Berucksichtigung der Alterdisposition in Hamburg 1939 bis 1958 Dtsch Med Wochenschr 1960. 85: 1081-1089. (PubMed)

127. C.A. van den Berg. L'encephalite post-vaccinale aux Pays-Bas Bull Office Intern Hyg Publique 1946. 38: 847-848.

128. J.M. Neff and J.M. Lane, et al. Complications of smallpox vaccination. I. National survey in the United States 1963 N Engl J Med 1967. 276: 125-132. (PubMed)

129. Berger K, Heinrich W. Decrease in postvaccinal deaths in Austria after introducing a less pathogenic virus strain. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization 19:199

203, 1973.

130. Marrenikova SS, Chimishkyan KL, Maltseva NN, et al. Characteristics of virus strains for production of smallpox vaccines. In Proceedings of the Symposium on Smallpox. Zagreb, Yugoslav Academy of Sciences and Arts, 1969, pp 65

79.

131. M.T. Bellows, M.R. Hyman, and K.K. Merritt, et al. Effect of smallpox vaccination on outcome of pregnancy Public Health Rep 1949. 64: 319-323.

132. L.J. Abramowitz. Vaccination and virus diseases during pregnancy S Afr Med J 1957. 31: 1-3. (PubMed)

133. G.J. Bourke. Smallpox vaccination in pregnancy; a prospective study Br Med J 1964. 5397: 1544-1546. (PubMed)

134. Communicable Disease Center. Manual of Operations: West and Central Africa Smallpox Eradication/Measles Control Program. Atlanta, Centers for Disease Control, 1966.

135. G. Tondury and M. Foukas. Die Gefahrdung des menschlichen Keimlings durch Pockenimpfimg in Graviditate Pathol Microbiol 1964. 27: 602-623.

136. W.L. Marmelzat. Malignant tumors in smallpox vaccination scars. A report of 24 cases Arch Dermatol 1968. 97: 400-406. (PubMed)

137. S. Sewall. Vaccinia osteomyelitis. Report of a case with isolation of the vaccinia virus Bull Hosp Jt Dis 1949. 10: 59-63.

138. J.A. Umer. Some observations of the vaccination of pregnant women and newborn infants Am J Obstet Gynecol 1927. 13: 70-76.

139. B.L. Lieberman. Vaccination of pregnant women and newborn infants Am J Obstet Gynecol 1927. 14: 217-220.

140. H.H. Donnally and M.M. Nicholson. A study of vaccination in five hundred newborn infants JAMA 1934. 103: 1269-1275.

141. I.M. Webster. The response of leprosy patients to smallpox vaccine West Afr Med J 1959. 8: 322-324. (PubMed)

142. S.G. Browne and E.M. Davis. Reaction in leprosy precipitated by smallpox vaccination Lepr Rev 1962. 33: 252-254. (PubMed)

143. Blake JB. Benjamin Waterhouse and the Introduction of Vaccination; a Reappraisal. Philadelphia, University of Pennsylvania Press, 1957.

144. Halsey RH. How the President, Thomas Jefferson and Dr. Benjamin Waterhouse established vaccination as a public health procedure. History of Medicine Series No. 5. New York, New York Academy of Medicine, 1936.

145. C.V. Chapin and J. Smith. Permanency of the mild type of smallpox J Preventive Med 1932. 6: 273-320.

146. V.C. Vaughan. Smallpox before and after Edward Jenner Hygeia 1923. 1: 205-211.

147. S.B. Woodward and R.F. Feemster. The relation of smallpox morbidity to vaccination laws N Engl J Med 1933. 208: 317-318.

148. J.P. Leake. Questions and answers on smallpox vaccination Public Health Rep 1927. 42: 221-238.

149. Low RB. The Incidence of Small-pox Throughout the World in Recent Years. Reports to the Local Government Board on Public Health and Medical Subjects NS No. 117. London, His Majesty's Stationery Office, 1918.

150. Henneberg G. The distribution of smallpox in Europe 1919

1948. In Rodenwaldt E, Jusatz HJ (eds). World-Atlas of Epidemic Diseases, Part II. Hamburg, Falk-Verlag, 1956, pp 67

72.

151. B.A. Rodrigues. Smallpox eradication in the Americas Bull Pan Am Health Organ 1975. 9: 53-68. (PubMed)

152. Arita I, Henderson DA. Freeze-dried vaccine for the smallpox eradication programme. In Proceedings of the Symposium on Smallpox. Zagreb, Yugoslav Academy of Sciences and Arts, 1969, pp 39

50.

153. Arita I. The control of vaccine quality in the smallpox eradication programme. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization 19:79

87, 1973.

154. Henderson DA, Arita I, Shafa E. Studies of the bifurcated needle and recommendations for its use. Unpublished document. Geneva, World Health Organization, 1969.

155. T.M. Mack, D.B. Thomas, A. Ali, and M.M. Khan. Epidemiology of smallpox in West Pakistan. 1. Acquired immunity and the distribution of disease Am J Epidemiol 1972. 95: 157-168. (PubMed)

156. W.H. Foege, J.D. Millar, and J.M. Lane. Selective epidemiologic control in smallpox eradication Am J Epidemiol 1971. 94: 311-315. (PubMed)

157. World Health Organization. Report of the WHO Ad Hoc Committee on Orthopoxvirus Infections. Wkly Epidemiol Rec 6:289, 1986.

158. B.W.J. Mahy, J.W. Almond, and K.I. Bems, et al. The remaining stocks of smallpox virus should be destroyed Science 1993. 262: 1223-1224. (PubMed)

159. B. Roizman, W. Joklik, B. Fields, and B. Moss. The destruction of smallpox virus stocks in national repositories: A grave mistake and a bad precedent Infect Agents Dis 1994. 3: 215-217. (PubMed)

160. World Health Organization. Report of the Ad Hoc Committee on Orthopoxvirus Infections. Executive Board Report EB 95/33 dated October 10, 1994.

161. M. Mackett, G.L. Smith, and B. Moss. Vaccinia virus: A selectable eukaryotic cloning and expression vector Proc Natl Acad Sci USA 1982. 79: 7415-7419. (PubMed) (Full Text in PMC)

162. D. Panicali and E. Paoletti. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus Proc Natl Acad Sci USA 1982. 79: 4927-4931. (PubMed) (Full Text in PMC)

163. G.L. Smith and B. Moss. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA Gene 1983. 25: 21-28. (PubMed)

164. M.E. Perkus, A. Piccini, B.R. Lipinskas, and E. Paoletti. Recombinant vaccinia virus: Immunization against multiple pathogens Science 1985. 229: 981-984. (PubMed)

165. B. Moss. Vaccinia virus: A tool for research and vaccine development Science 1991. 252: 1662-1667. (PubMed)

166. F. Fenner and B.M. Comben. Genetic studies with mammalian poxviruses. I. Demonstration of recombination between two strains of poxviruses Virology 1958. 5: 530-548. (PubMed)

167. C.K. Sam and K.R. Dumbell. Expression of poxvirus DNA in coinfected cells and marker rescue of thermosensitive mutants by subgenomic fragments of DNA Ann Viral 1981. 132E: 135-150.

168. E. Nakano, D. Panicali, and E. Paoletti. Molecular genetics of vaccinia virus: Demonstration of marker rescue Proc Natl Acad Sci USA 1982. 79: 1593-1596. (PubMed) (Full Text in PMC)

169. J.P. Weir, G. Bajszar, and B. Moss. Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA Proc Natl Acad Sci USA 1982. 79: 1210-1214. (PubMed) (Full Text in PMC)

170. M. Mackett, G.L. Smith, and B. Moss. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes J Virol 1984. 49: 857-864. (PubMed) (Full Text in PMC)

171. Earl PL, Moss B. Generation of recombinant vaccinia viruses. In Ausubel FM, Brent R, Kingston RE, et al (eds). Current Protocols in Molecular Biology. New York, Greene Publishing Associates & Wiley Interscience, 1991, pp 16.17.11

16.17.16.

172. A.J. Davison and B. Moss. The structure of vaccinia virus early promoters J Mol Biol 1989. 210: 749-769. (PubMed)

173. A.J. Davison and B. Moss. The structure of vaccinia virus late promoters J Mol Biol 1989. 210: 771-784. (PubMed)

174. B. Moss. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety Proc Natl Acad Sci USA 1996. 93: 11341-11348. (PubMed) (Full Text in PMC)

175. Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication. Geneva, World Health Organization, 1988.

176. E.L. Cooney, A.C. Collier, and P.D. Greenberg, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein Lancet 1991. 337: 567-572. (PubMed)

177. R.M.L. Buller, G.L. Smith, and K. Cremer, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype Nature 1985. 317: 813-815. (PubMed)

178. S.L. Lee, J.M. Roos, and L.C. McGuigan, et al. Molecular attenuation of vaccinia virus: Mutant generation and animal characterization J Virol 1992. 66: 2617-2630. (PubMed) (Full Text in PMC)

179. R.M.L. Buller and G.J. Palumbo. Poxvirus pathogenesis Microbiol Rev 1991. 55: 80-122. (PubMed) (Full Text in PMC)

180. J. Tartaglia, M.E. Perkus, and J. Taylor, et al. NYVAC-a highly attenuated strain of vaccinia virus Virology 1992. 188: 217-232. (PubMed)

181. E. Konishi, S. Pincus, and E. Paoletti, et al. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NSl genes of Japanese encephalitis virus prevents JEV viremia in swine Virology 1992. 190: 454-458. (PubMed)

182. C.B. Stephenson, J. Welter, and S.R. Thaker, et al. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC and ALVAC-based CDV recombinants protect against symptomatic infection J Virol 1997. 71: 1506-1513. (PubMed) (Full Text in PMC)

183. A. Mayr, V. Hochstein-Mintzel, and H. Stickl. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-stammes MVA Infection 1975. 3: 6-14.

184. H. Sticl, V. Hochstein-Mintzel, and A. Mayr, et al. MVA-Stufenimpfung gegen Pocken. Klinische Erprobung des attenuierten Pocken-lebendimpfstoffes, Stamm MVA Dtsch Med Wochenschr 1974. 99: 2386-2392. (PubMed)

185. G. Sutter and B. Moss. Non-replicating vaccinia vector efficiently expresses recombinant genes Proc Natl Acad Sci USA 1992. 89: 10847-10851. (PubMed) (Full Text in PMC)

186. G. Sutter, L.S. Wyatt, and P.L. Foley, et al. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus Vaccine 1994. 12: 1032-1040. (PubMed)

187. V.M. Hirsch, T.R. Fuerst, and G. Sutter, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara J Virol 1996. 70: 3741-3752. (PubMed) (Full Text in PMC)

188. L.S. Wyatt, S.T. Shors, B.R. Murphy, and B. Moss. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model Vaccine 1996. 14: 1451-1458. (PubMed)

189. J.R. Bennink, J.W. Yewdell, and J.W. Smith, et al. Recombinant vaccinia virus primes and stimulates influenza virus HA-specific CTL Nature 1984. 311: 578-579. (PubMed)

190. J.W. Yewdell, J.R. Bennink, G.L. Smith, and B. Moss. Influenza A virus nucleoprotein is a major target for cross-reactive anti-influenza virus cytotoxic T lymphocytes Proc Natl Acad Sci USA 1985. 82: 1785-1789. (PubMed) (Full Text in PMC)

191. B.D. Walker, S. Chakrabarti, and B. Moss, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals Nature 1987. 328: 345-348. (PubMed)

192. B.D. Walker, C. Flexner, and T.J. Paradis, et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals Science 1988. 240: 64-66. (PubMed)

193. J.R. Bennink and J.W. Yewdell. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function Curr Top Microbiol Immunol 1990. 163: 153-184. (PubMed)

194. A. Otteken, P.L. Earl, and B. Moss, et al. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates J Virol 1996. 70: 3407-3415. (PubMed) (Full Text in PMC)

195. R.A. Olmsted, N. Elango, and G.A. Prince, et al. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: Comparison of the individual contributions of the F and G glycoproteins to host immunity Proc Natl Acad Sci USA 1986. 83: 7462-7466. (PubMed)

196. M.K. Spriggs, B.R. Murphy, and G.A. Prince, et al. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: Contributions of the individual proteins to host immunity J Virol 1987. 61: 3416-3423. (PubMed) (Full Text in PMC)

197. R.G. Paterson, R.A. Lamb, B. Moss, and B.R. Murphy. Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity J Virol 1987. 61: 1972-1977. (PubMed) (Full Text in PMC)

198. M. Connors, A.B. Kulkarni, and P.L. Collins, et al. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (VacM2) is mediated by CD8⁺ T cells, while that induced by Vac-F or Vat-G recombinants is mediated by antibodies J Virol 1992. 66: 1277-1281. (PubMed) (Full Text in PMC)

199. M.E. Andrew, B.E.H. Coupar, D.B. Boyle, and G.L. Ada. The roles of influenza virus haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice Scand J Immunol 1987. 25: 21-28. (PubMed)

200. B. Moss, G.L. Smith, J.L. Gerin, and R.H. Purcell. Live recombinant vaccinia virus protects chimpanzees against hepatitis B Nature 1984. 311: 67-69. (PubMed)

201. Flexner C, Moss B. New generation vaccines. In Levine MM, Woodrow GC, Kasper JB, Cobon GS (eds). New Generation Vaccines. New York, Marcel Dekker, 1997, pp 297

314.

202. R. Bemards, A. Destree, and S. McKenzie, et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector Proc Natl Acad Sci USA 1987. 84: 6854-6858. (PubMed) (Full Text in PMC)

203. C.D. Estin, U.S. Stevenson, and G.D. Plowman, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy Proc Natl Acad Sci USA 1988. 85: 1052-1056. (PubMed) (Full Text in PMC)

204. J. Kantor, K. Irvine, and S. Abrams, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate Cancer Res 1992. 52: 6917-6925. (PubMed)

205. M.W. Carroll, W.W. Overwiijk, and R.S. Chamberlain, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model Vaccine 1997. 15: 387-394. (PubMed)

206. D.B. Bovle and B.E.H. Counar. Construction of recombinant fowlpox viruses as vectors for poultry vaccines Virus Res 1988. 10: 343-356. (PubMed)

207. C.H. Romero, T. Barrett, and S.A. Evans, et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinder pest and lumpy skin disease Vaccine 1993. 11: 737-742. (PubMed)

208. J. Taylor, R. Weinberg, and B. Languet, et al. Recombinant fowlpox virus inducing protective immunity in non-avian species Vaccine 1988. 6: 497-503. (PubMed)

209. P. Somogyi, J. Frazier, and M.A. Skinner. Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells Virology 1993. 197: 439-444. (PubMed)

210. D.J. Langford, S.J. Edwards, and G.L. Smith, et al. Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus infected cells increases its immunogenicity Mol Cell Biol 1986. 6: 3191-3199. (PubMed) (Full Text in PMC)

211. G.W. Both, M.E. Andrew, and D.B. Boyle, et al. Relocation of antigens to the cell surface membrane can enhance immune stimulation and protection Immunol Cell Biol 1992. 70: 73-78. (PubMed)

212. A.J. Ramsay, A.J. Ramsay, and K.H. Leong, et al. Vector-encoded interleukin-5 and interleukin-6 enhance specific mucosal immunoglobulin A reactivity in vivo Adv Exp Med Biol 1995. 317A: 35-42. (PubMed)

213. R.S. Chamberlain, M.W. Carroll, and V. Bronte, et al. Costimulation enhances the active immunotherapy effect of recombinant anti-cancer vaccines Cancer Res 1996. 56: 2832-2836. (PubMed)

214. V. Bronte, K. Tsung, and J.B. Rao, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases J Immunol 1995. 154: 5282-5292. (PubMed)

215. A.C. Hekker, J.M. Bos, and L. Smith. A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells J Biol Stand 1973. 1: 21-32.

216. B.S. Graham, R.B. Belshe, and M.L. Clements, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type-1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial J Infect Dis 1992. 166: 244-252. (PubMed)

217. P.L. Earl, A.W. Hugin, and B. Moss. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus J Virol 1990. 64: 2448-2451. (PubMed) (Full Text in PMC)

218. E.L. Cooney, M.J. McElrath, and L. Corey, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160-protein Proc Natl Acad Sci USA 1993. 90: 1882-1886. (PubMed) (Full Text in PMC)

219. B.S. Graham, T.J. Matthews, and R.B. Belshe, et al. Augmentation of human immunodeficiency virus type-l neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgpl60 in vaccinia-naive adults J Infect Dis 1993. 167: 533-537. (PubMed)

220. G. Pialoux, J.L. Excler, and Y. Riviere, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI) AIDS Res Hum Retroviruses 1995. 11: 373-381. (PubMed)

221. M. Egan, W. Ravlat, and J. Tartaglia, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a non-replicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 _MN env gene J Infect Dis 1995. 171: 1623-1627. (PubMed)

222. B. Fleury, G. Janvier, and G. Pialoux, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-l)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160 J Infect Dis 1996. 174: 734-738. (PubMed)

223. S.Y. Gu, T.M. Huang, and L. Ruan, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen Dev Biol Stand 1995. 84: 171-177. (PubMed)

224. M. Cadoz, A. Strady, and B. Meignier, et al. Immunization with canarypox virus expressing rabies glycoprotein Lancet 1992. 339: 1429-1432. (PubMed)

225. L.F. Fries, J. Tartaglia, and J. Taylor, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system Vaccine 1996. 14: 428-434. (PubMed)

226. Fenner F, Gibbs EPJ, Murphy FA, et al. Veterinary Virology (2nd ed). San Diego, CA, Academic Press, 1993.

227. M. Mackett, T. Yilma, J.K. Rose, and B. Moss. Vaccinia virus recombinants: Expression of VSV genes and protective immunization of mice and cattle Science 1985. 227: 433-435. (PubMed)

228. L. Giavedoni, L. Jones, C. Mebus, and T. Yilma. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions Proc Natl Acad Sci USA 1991. 88: 8011-8015. (PubMed) (Full Text in PMC)

229. S.L. Brockmeier, K.M. Lager, and J. Tartaglia, et al. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses Vet Microbiol 1993. 38: 41-58. (PubMed)

230. T.M. Chambers, Y. Kawaoka, and R.G. Webster. Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin Virology 1988. 167: 414-421. (PubMed)

231. T.J. Wiktor, R.I. Macfarlan, and K.J. Reagan, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene Proc Natl Acad Sci USA 1984. 81: 7194-7198. (PubMed) (Full Text in PMC)

232. C.E. Rupprecht, T.J.A. Wiktor, and D.H. Johnston, et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine Proc Natl Acad Sci USA 1986. 83: 7947-7950. (PubMed) (Full Text in PMC)

233. B. Brochier, F. Costy, and P.P. Pastoret. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: An update Vet Microbiol 1995. 46: 269-279. (PubMed)

234. J.J. Esposito, J.C. Knight, and J.H. Shaddock, et al. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein Virology 1988. 165: 313-316. (PubMed)

235. C.H. Romero, T. Barrett, and R.W. Chamberlain, et al. Recombinant capripoxvirus expressing the hernagglutinin protein gene of rinderpest virus: Protection of cattle against rinderpest and lumpy skin disease Virology 1994. 204: 425-429. (PubMed)

236. M.L. van der Leek, J.A. Feller, and G. Sorenson, et al. Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63 Vet Rec 1994. 134: 13-18. (PubMed)

237. R.G. Webster, Y. Kawaoka, and J. Taylor, et al. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens Vaccine 1991. 9: 303-308. (PubMed)

238. M.E. Boursnell, P.F. Green, and A.C. Samson, et al. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV Virology 1990. 178: 297-300. (PubMed)

239. C. Edbauer, R. Weinberg, and J. Taylor, et al. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene Virology 1990. 179: 901-904. (PubMed)

240. C.D. Bayliss, R.W. Peters, and J.K.A. Cook, et al. A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus Arch Virol 1991. 120: 193-205. (PubMed)

241. J. Tartaglia, O. Jarrett, and J.C. Neil, et al. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL J Virol 1993. 67: 2370-2375. (PubMed) (Full Text in PMC)